Search results for "gero"

showing 10 items of 2629 documents

Análisis de biopsias líquidas para el diagnóstico del cáncer: revisión sistemática

2020

The incidence of cancer has increased in recent years, especially in those over 65 years of age, posing a major health problem. Many tumours have a poor prognosis because they are diagnosed at very advanced stages. It is therefore especially important to incorporate liquid biopsy into clinical practice as a method for detecting tumours at very early stages. A systematic review was conducted, with the main objective of analysing the available literature on the use of liquid biopsy in the early diagnosis of cancer, and as a secondary objective, to determine the types of tumours that can be diagnosed early by liquid biopsy and the available biomarkers. The results indicate a lack of agreement …

0301 basic medicineOncologyAgingmedicine.medical_specialtyPoor prognosisScreening testbusiness.industryIncidence (epidemiology)Advanced stageMedicine (miscellaneous)Cancermedicine.diseaseClinical Practice03 medical and health sciences030104 developmental biology0302 clinical medicine030220 oncology & carcinogenesisInternal medicinemedicineGeriatrics and GerontologyLiquid biopsybusinessRevista Española de Geriatría y Gerontología
researchProduct

Circulating Molecular Chaperones in Subjects with Amnestic Mild Cognitive Impairment and Alzheimer’s Disease: Data from the Zabùt Aging Project

2022

Molecular chaperones play essential roles in many processes such as cell differentiation, tissue homeostasis, and organ remodeling. Recent data indicate that chaperones can act as cytoprotectants for brain cells during the progression of neurodegenerative diseases, including Alzheimer’s disease (AD). However, very few data on the levels of chaperones in dementia, including its prodromal phases, have been reported. In this study, we used biological samples and epidemiological data collected during the Zabùt Aging Project (a prospective, community-based, cohort study of normal/pathological aging conducted in Sicily, Italy, with a follow-up of ten years) to determine if there is an association…

0301 basic medicineOncologyAgingmedicine.medical_specialtySettore MED/09 - Medicina InternaHsp90DiseaseNeuropsychological Testsmedicine.disease_causeHsp70Cohort Studies03 medical and health sciences0302 clinical medicineAlzheimer DiseaseInternal medicineEpidemiologyoxidative stressHumansMedicineDementiaCognitive DysfunctionProspective StudiesPathologicalTissue homeostasiscognitive impairmentSettore MED/04 - Patologia Generalebusiness.industryGeneral NeuroscienceNeurodegenerationneurodegenerationGeneral Medicinemolecular chaperoneHsp60medicine.diseasePsychiatry and Mental healthClinical Psychology030104 developmental biologySettore MED/26 - NeurologiaGeriatrics and GerontologybusinessAlzheimer’s disease030217 neurology & neurosurgeryOxidative stressMolecular ChaperonesCohort studyJournal of Alzheimer's Disease
researchProduct

Red Blood Cell Distribution Width, Vascular Aging Biomarkers, and Endothelial Progenitor Cells for Predicting Vascular Aging and Diagnosing/Prognosin…

2018

The emerging evidence emphasizes Red blood cell distribution width (RDW) as optimal prognostic biomarker for cardiovascular diseases. However, several clinical biases impede its clinical application. Recent recommendations suggest combining RDW with other biomarkers. Accordingly, we propose evaluating the well-recognized biomarkers of vascular aging (i.e., the leukocyte telomere length and telomerase activity, and reduced levels of endothelial progenitor cells [EPCs]) with RDW, for predicting the risk for vascular aging and onset and prognosis of age-related degenerative arterial diseases, such as sporadic ascending aorta aneurysm (AAA), characterized to have an increased incidence in old p…

0301 basic medicineOncologyErythrocyte IndicesMaleTelomeraseAgingEPCs; RDW; diagnostic and prognostic AAA biomarkers; leukocyte telomere length; risk for vascular aging and sporadic AAA; telomere activityArterial diseaserisk for vascular aging and sporadic AAA0302 clinical medicineRisk FactorsLeukocytesMedicinetelomere activityEndothelial Progenitor CellsAged 80 and overMiddle AgedTelomerePrognosisAortic AneurysmC-Reactive Proteincardiovascular systemBiomarker (medicine)Vascular agingFemaleAdultmedicine.medical_specialtydiagnostic and prognostic AAA biomarkersleukocyte telomere length03 medical and health sciencesYoung AdultInternal medicinemedicine.arterySettore MED/05 - Patologia ClinicaRDWHumansVascular DiseasesProgenitor cellAgedAortabusiness.industrySettore MED/23 - Chirurgia CardiacaRed blood cell distribution widthEPCTelomere030104 developmental biologyCase-Control StudiesEPCsGeriatrics and Gerontologybusinessdiagnostic and prognostic AAA biomarker030217 neurology & neurosurgeryBiomarkersRejuvenation research
researchProduct

Oxidative stress and frailty : a systematic review and synthesis of the best evidence

2017

Objective Oxidative stress (OS) is associated with accelerated aging. Previous studies have suggested a possible relationship between OS and frailty but this association remains unclear. We conducted a systematic review to investigate potential interactions between OS and frailty. Methods A systematic literature search of original reports providing data on ‘OS and antioxidant’ parameters and frailty was carried out across major electronic databases from inception until May 2016. Cross-sectional/case control and longitudinal studies reporting data on the association between frailty and anti-oxidants-OS biomarkers were considered for inclusion. Results were summarized with a synthesis based o…

0301 basic medicineOncologyGerontologyGenetics and Molecular Biology (all)AgingCross-sectional studyalpha-TocopherolAntioxidantesIsoprostanesmedicine.disease_causeBiochemistryAnti-oxidantAntioxidants0302 clinical medicineLongitudinal StudiesAged 80 and overFrailtyGlutathione DisulfideObstetrics and GynecologyGlutathione8-Hydroxy-2'-DeoxyguanosineSystematic searchAnti-oxidant; Frail; Frailty; Oxidative stress; Biochemistry Genetics and Molecular Biology (all); Obstetrics and Gynecologymedicine.medical_specialtyFrail ElderlyGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesFrailInternal medicinemedicineHumansFrail elderlySulfhydryl CompoundsAgedAldehydesbusiness.industryCase-control studyFrailty Frail Oxidative stress Anti-oxidantEstresse OxidativoDeoxyguanosineMean ageOxidized GlutathioneOxidative Stress030104 developmental biologyCross-Sectional Studies1-Alkyl-2-acetylglycerophosphocholine EsteraseBest evidencebusinessReactive Oxygen Species030217 neurology & neurosurgeryOxidative stressBiomarkers
researchProduct

Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells.

2017

// James A. McCubrey 1 , Timothy L. Fitzgerald 2 , Li V. Yang 3 , Kvin Lertpiriyapong 4 , Linda S. Steelman 1 , Stephen L. Abrams 1 , Giuseppe Montalto 5,6 , Melchiorre Cervello 6 , Luca M. Neri 7 , Lucio Cocco 8 , Alberto M. Martelli 8 , Piotr Laidler 9 , Joanna Dulinska-Litewka 9 , Dariusz Rakus 10 , Agnieszka Gizak 10 , Ferdinando Nicoletti 11 , Luca Falzone 11 , Saverio Candido 11 and Massimo Libra 11 1 Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC, USA 2 Department of Surgery, Brody School of Medicine at East Carolina University, Greenville, NC, USA 3 Department of Internal Medicine, Hematology/Oncology Section, Brody Sc…

0301 basic medicineOncologyGerontologycancer stem cellsmedicine.medical_specialtyEpithelial-Mesenchymal TransitionReviewPI3KNO03 medical and health sciencesGlycogen Synthase Kinase 30302 clinical medicineCancer stem cellGSK-3Internal medicinemicroRNAmedicineAnimalsHumansPTENEpithelial–mesenchymal transitionProtein kinase BPI3K/AKT/mTOR pathwayGSK-3biologybusiness.industryAnimalCancer stem cellAktWnt signaling pathwayWnt/beta-cateninMicroRNAMicroRNAsGSK-3 cancer stem cells Wnt/beta-catenin PI3K Akt030104 developmental biologyOncology030220 oncology & carcinogenesisNeoplastic Stem Cellsbiology.proteinNeoplastic Stem CellAkt; GSK-3; PI3K; Wnt/beta-catenin; cancer stem cellsbusinessHumanSignal Transduction
researchProduct

EGFR inhibition in NSCLC: New findings…. and opened questions?

2017

The targeted inhibition of epidermal growth factor receptor (EGFR) has represented a milestone in the treatment of lung cancer. Several studies convincingly and consistently demonstrated a significant superiority of EGFR-TKIs over standard platinum-chemotherapy in EGFR-mutated NSCLC patients, leading to the sequential approval of gefitinib, erlotinib and afatinib as new standard first-line clinical treatment. To date we are witnessing a second revolution in the management of EGFR-positive NSCLC thanks to the development of new treatment strategies aiming to overcome acquired resistance to TKIs and ultimately improve patients’ outcomes. In this review we summarize the most important recent f…

0301 basic medicineOncologyLung Neoplasmsmedicine.medical_treatmentAfatinibResistanceTreatment of lung cancerTargeted therapyTargeted therapyAntineoplastic Agent0302 clinical medicineEpidermal growth factorEpidermal growth factor receptorMolecular Targeted TherapybiologyHematologyTKIErbB ReceptorsOncology030220 oncology & carcinogenesisErlotinibReceptorHumanmedicine.drugmedicine.medical_specialtyEGFR; Liquid biopsy; Resistance; Targeted therapy; TKIs; Antineoplastic Agents; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Receptor Epidermal Growth Factor; Hematology; Oncology; Geriatrics and GerontologyEGFRProtein Kinase InhibitorAntineoplastic Agents03 medical and health sciencesGefitinibInternal medicinemedicineHumansLiquid biopsyIntensive care medicineProtein Kinase InhibitorsEGFR; Liquid biopsy; Resistance; Targeted therapy; TKIs; Antineoplastic Agents; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Receptor; Epidermal Growth Factor; Hematology; Oncology; Geriatrics and GerontologyEpidermal Growth FactorLiquid biopsybusiness.industryrespiratory tract diseasesLung Neoplasm030104 developmental biologyTKIsMutationbiology.proteinReceptor Epidermal Growth FactorGeriatrics and Gerontologybusiness
researchProduct

Serum Levels of Clusterin, PKR, and RAGE Correlate with Amyloid Burden in Alzheimer's Disease.

2021

Background: Alzheimer’s disease (AD) is the most common form of dementia and biomarkers are essential to help in the diagnosis of this disease. Image techniques and cerebrospinal fluid (CSF) biomarkers are limited in their use because they are expensive or invasive. Thus, the search for blood-borne biomarkers is becoming central to the medical community. Objective: The main objective of this study is the evaluation of three serum proteins as potential biomarkers in AD patients. Methods: We recruited 27 healthy controls, 19 mild cognitive impairment patients, and 17 AD patients. Using the recent A/T/N classification we split our population into two groups (AD and control). We used ELISA kits…

0301 basic medicineOncologyMalemedicine.medical_specialtyPopulationDiseaseRAGE (receptor)03 medical and health scienceseIF-2 Kinase0302 clinical medicineCerebrospinal fluidAlzheimer DiseaseAntigens NeoplasmInternal medicinemedicineDementiaHumanseducationAgedAged 80 and overeducation.field_of_studyAmyloid beta-PeptidesClusterinbiologybusiness.industryGeneral NeuroscienceGeneral MedicineMiddle Agedmedicine.diseaseBlood proteinsProtein kinase RPsychiatry and Mental healthClinical Psychology030104 developmental biologyClusterinbiology.proteinFemaleGeriatrics and GerontologyMitogen-Activated Protein Kinasesbusiness030217 neurology & neurosurgeryBiomarkersJournal of Alzheimer's disease : JAD
researchProduct

Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis.

2016

Clinical trials investigated the potential role of both KRAS and BRAF mutations, as prognostic biomarkers, in colorectal cancer (CRC) patients who underwent surgical treatment of CRC-related liver metastases (CLM), showing conflicting results. This meta-analysis aims to review all the studies reporting survival outcomes (recurrence free survival (RFS), and/or overall survival (OS)) of patients undergoing resection of CLM, stratified according to KRAS and/or BRAF mutation status. Background: Clinical trials investigated the potential role of both KRAS and BRAF mutations, as prognostic biomarkers, in colorectal cancer (CRC) patients who underwent surgical treatment of CRC-related liver metast…

0301 basic medicineOncologyendocrine system diseasesColorectal cancerLiver metastasimedicine.medical_treatmentColorectal Neoplasmmedicine.disease_cause0302 clinical medicineLiver metastasisHematologyTumorLiver NeoplasmsHematologyPrognosisSurvival RateOncologyLiver Neoplasm030220 oncology & carcinogenesisMeta-analysisKRASColorectal NeoplasmsHumanProto-Oncogene Proteins B-rafmedicine.medical_specialtyPrognostic biomarkerPrognosiResectionBRAFProto-Oncogene Proteins p21(ras)03 medical and health sciencesInternal medicineBRAF; Colorectal cancer; KRAS; Liver metastasis; Prognostic biomarker; Biomarkers Tumor; Colorectal Neoplasms; Humans; Liver Neoplasms; Mutation; Prognosis; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Survival Rate; Hepatectomy; Oncology; Hematology; Geriatrics and GerontologymedicineKRASBiomarkers TumorHepatectomyHumansneoplasmsSurvival ratebusiness.industrymedicine.diseaseColorectal cancerdigestive system diseasesClinical trial030104 developmental biologyMutationBRAF; Colorectal cancer; KRAS; Liver metastasis; Prognostic biomarker; Biomarkers; Tumor; Colorectal Neoplasms; Humans; Liver Neoplasms; Mutation; Prognosis; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Survival Rate; Hepatectomy; Oncology; Hematology; Geriatrics and GerontologyHepatectomyGeriatrics and GerontologybusinessBiomarkersCritical reviews in oncology/hematology
researchProduct

Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized pha…

2017

Abstract Objectives To determine predictive/prognostic factors for patients with metastatic breast cancer (MBC) receiving first-line monochemotherapy using biomarker analysis and geriatric assessment (GA). Materials and Methods Karnofsky Performance Status (KPS) and GA as clinical parameters, and prognostic inflammatory and nutritional index (PINI), and Glasgow prognostic score (GPS) as biomarkers were analyzed for association with clinical outcome within the randomized phase III PEg-LIposomal Doxorubicin vs. CApecitabin iN MBC (PELICAN) trial of first-line pegylated liposomal doxorubicin (PLD) or capecitabine. Results Of 210 patients, 38% were > 65 years old. GA (n = 152) classified 74% as…

0301 basic medicineOncologymedicine.medical_specialtyMultivariate analysisAnthracyclinemedicine.medical_treatmentBreast NeoplasmsPolyethylene GlycolsCapecitabine03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansDoxorubicinKarnofsky Performance StatusGeriatric AssessmentCapecitabineAgedChemotherapyFrailtybusiness.industryAge FactorsGeriatric assessmentMiddle Agedmedicine.diseaseMetastatic breast cancer030104 developmental biologyTreatment OutcomeOncologyDoxorubicin030220 oncology & carcinogenesisDisease ProgressionBiomarker (medicine)FemaleGeriatrics and GerontologybusinessBiomarkersmedicine.drugJournal of geriatric oncology
researchProduct

Melanoma of unknown primary: New perspectives for an old story

2021

Melanoma of unknown primary site (MUP) comprises 3-4 % of all melanomas. It mostly presents in lymph nodes (LNs), followed by subcutaneous sites, and visceral organs; nevertheless, there is a trend of increase in the relative incidence of visceral counterpart in recent years. Spontaneous regression of the primary lesion is a well-established theory, based on the evidence that melanoma can undergo regression at the primary site. MUP and stage-matched melanoma of known primary site (MKP) share similar prognostic factors. The survival rate of patients with MUP has been compared to those with stage-matched MKP. Multiple studies conducted before the era of novel therapy with immune checkpoint or…

0301 basic medicineOncologymedicine.medical_specialtymedicine.medical_treatment2720 Hematology610 Medicine & healthTargeted therapy03 medical and health sciences0302 clinical medicineInternal medicineEpidemiologymedicineHumansMelanomaSurvival rateHematologybusiness.industryIncidenceMelanomaIncidence (epidemiology)General MedicineHematologyImmunotherapymedicine.disease10174 Clinic for GynecologyImmune checkpointSurvival Rate030104 developmental biologyOncology030220 oncology & carcinogenesisNeoplasms Unknown Primary2730 OncologyLymph NodesGeriatrics and GerontologybusinessCritical Reviews in Oncology/Hematology
researchProduct